Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT03577665 |
Title为结直肠癌肝转移患者提供治愈性质子束疗法 | 阶段
不适用
|
Date Added 2018-07-05 |
地点
大韩民国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04687631 |
Title最初无法切除肝转移灶的 RAS/BRAF 野生型结直肠癌患者的转换疗法 | 阶段
第三阶段
|
Date Added 2020-12-29 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
mFOLFOXIRI Plus Bevacizumab, mFOLFOXIRI plus Cetuximab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05768503 |
TitleComparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC | 阶段
第三阶段
|
Date Added 2023-03-14 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Control Rx, Experimental drug |
标签
MSS/ MMRp
|
| NCT ID NCT05990543 |
TitleCombination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer | 阶段
第 1 阶段
|
Date Added 2023-08-14 |
地点 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
尚未招聘
|
药物
Nelmastobart and Capecitabine |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT02997228 |
TitleCombination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study | 阶段
第三阶段
|
Date Added 2016-12-20 |
地点
Arizona, United States
Arkansas, United States California, United States Colorado, United States Connecticut, United States Delaware, United States District of Columbia, United States Florida, United States Georgia, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maine, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States New York, United States North Carolina, United States North Dakota, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Virginia, United States Washington, United States West Virginia, United States Wisconsin, United States Wyoming, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
暂停
|
药物
Atezolizumab, fluorouracil, Leucovorin, oxaliplatin |
标签
MSI-H/ MMRd
|
| NCT ID NCT03088150 |
TitleCOLLISION 试验 - 结直肠肝转移：手术与热消融 | 阶段
第三阶段
|
Date Added 2017-03-23 |
地点
荷兰
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
Unknown status
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06185556 |
TitleCOLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases | 阶段
第二阶段
|
Date Added 2023-12-29 |
地点
荷兰
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05999812 |
TitleClinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer | 阶段
第二阶段
|
Date Added 2023-08-21 |
地点
Texas, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
all trans Retinoic Acid, Atezolizumab, Bevacizumab |
标签
MSS/ MMRp
|
| NCT ID NCT05676190 |
TitleClinical Study on the Efficacy of Autologous Cell Factor Induced Killer Cells in the Treatment of Colorectal Cancer | 阶段
不适用
|
Date Added 2023-01-09 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06026774 |
TitleClinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive System Neoplasms | 阶段
第 1 阶段
|
Date Added 2023-09-07 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
